Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554376 | 0.84 | ACHE (0.41) | ACHECHRM5ADRA2C | |
| SCHEMBL19723150 | 0.82 | KDM4E (0.37) | ACHECHRM5ADRA2CKCNH2 | |
| SCHEMBL2760188 | 0.80 | SMN1; SMN2 (0.42) | ACHEKCNH2 | |
| SCHEMBL2842528 | 0.78 | ACHE (0.47) | ACHECHRM5ADRA2C | |
| SCHEMBL8728949 | 0.77 | KCNH2 (0.38) | ACHEKCNH2 | |
| SCHEMBL22878502 | 0.77 | PABPC1 (0.46) | KCNH2 | |
| SCHEMBL23023333 | 0.73 | ACHE (0.47) | ACHECHRM5ADRA2C | |
| SCHEMBL8728946 | 0.73 | CARM1 (0.37) | KCNH2 | |
| SCHEMBL24673647 | 0.73 | ROCK2 (0.39) | ACHEKCNH2 | |
| SCHEMBL12395758 | 0.73 | ACHE (0.42) | ACHECHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | ACHE 4115/4885CHRM5 4550/4885ADRA2C 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.